Board of Directors

Juliet Bakker
Managing Director, Longitude Capital

Ms. Bakker is a founder and Managing Director of Longitude Capital. She focuses on investments in medical devices. Most recently, Ms. Bakker was a Managing Director of Pequot Ventures where she founded the life sciences investment practice in 1997. Prior to Pequot, she was Director, Strategic Planning and Director, Operations of Waste Management International, Inc. Ms. Bakker began her life sciences industry career over 20 years ago as an investment banker at PaineWebber. She currently serves on the boards of Ablation Frontiers, Acufocus, Aptus Endosystems, Facet Solutions, Paracor Medical, Sadra Medical and Sanarus Medical. Ms. Bakker holds an M.P.A. from the John F. Kennedy School of Government at Harvard University and a Bachelor of Science in Biological Sciences from Cornell University.

Garen Bohlin

Mr. Bohlin served as a senior executive in the life sciences/biotechnology industry for over 27 years and is currently focused solely on Board work and selective consulting. In his last industry position, he served as Executive Vice President of Constellation Pharmaceuticals, Inc. Previously he was the Chief Operating Officer for Sirtris Pharmaceuticals, Inc. which was acquired by Glaxo for more than $700 million. Prior to Sirtris, Mr. Bohlin served as President and C.E.O. of Syntonix Pharmaceuticals, Inc. and Executive Vice President of Genetics Institute where he was a key player in building the company over a 14 year period and oversaw its sale to Wyeth at an implied valuation of $3 billion. Prior to Mr. Bohlin’s tenure at Genetics Institute he spent 13 years at Arthur Andersen & Company where he became a partner. Mr. Bohlin currently serves as a director of Acusphere, Inc., Tetraphase Pharmaceuticals, Inc. and Karyopharm Therapeutics, Inc.

William Crouse
General Partner, HealthCare Ventures

Mr. Crouse has over 40 years of experience in venture capital investing and healthcare industry company management. Prior to his work with HealthCare Ventures, he served as Worldwide President of Ortho Diagnostic Systems, a subsidiary of Johnson & Johnson (J&J), and as Vice President of Johnson & Johnson International. Before joining J&J, Mr. Crouse also led international operations and worldwide commercial development activities as Division Director at DuPont Pharmaceuticals Company and served as President of Revlon Health Care Group’s companies in Latin America, Canada, and Asia/Pacific. He also held numerous management positions at pharmaceutical company, E.R. Squibb & Sons.

Mr. Crouse currently serves on the Board of Directors for The Medicines Company, a publicly traded biotechnology company and Uluru Inc., a publicly traded wound care and drug delivery company. He is also on the Board of Directors of four private biotechnology companies and has previously served on numerous other biotechnology and pharmaceutical company boards, including ImClone Systems Inc., Human Genome Sciences Inc., Delysys Pharmaceutical Corporation and Allelix Biopharmaceuticals Inc. Mr. Crouse earned a B.S. in Finance and Economics from Lehigh University and an M.B.A with Distinction in Marketing Management from Pace University.

Michael Heffernan, R.Ph.
Co-Founder, President, CEO, Collegium Pharmaceutical

Mr. Heffernan has 25 years of experience in the pharmaceutical and related healthcare industries. He is currently Co-Founder, President, CEO of Collegium Pharmaceutical. Collegium is a specialty pharmaceutical company focused on the development of pharmaceutical products for the treatment of chronic pain. He was previously the founder, President and CEO of Onset Therapeutics, a dermatology focused company that develops and commercializes products for the treatment of skin related illnesses. Michael held prior positions as Co-Founder, President and CEO of Clinical Studies Ltd., a pharmaceutical contract research organization that he successfully sold. He also served as President and CEO of PhyMatrix, a public $400 million integrated healthcare services company where he was hired to restructure the company.

Michael started his career at Eli Lilly and Company and served in numerous sales and marketing roles. He has also been a member of the Board of Directors, Advisor and Angel Investor in several healthcare companies. He is currently a member of the Board of Directors of TyRx, a venture backed medical device company, and Cornerstone Therapeutics (NASDAQ:CRTX), a specialty pharmaceutical company. Michael earned his B.S. Degree in Pharmacy from the University of Connecticut and is a Registered Pharmacist.

Patrick Heron
General Partner, Frazier Healthcare

Mr. Heron has nearly 20 years of experience in the consulting and healthcare industries, with a focus on early and later-stage private and public biotechnology companies. He has been active in company formation and initial investment including Marcadia (sold), a diabetes and obesity company, Calixa (sold), an anti-infectives company, and VentiRx, which is developing novel Toll-Like Receptor therapeutics. In specialty pharmaceuticals, he led Frazier’s involvement in MedPointe (sold), a specialty pharmaceutical company focused in the respiratory area.

Prior to joining Frazier Healthcare, Mr. Heron helped develop McKinsey & Co.’s West Coast biotechnology consulting practice. His projects included mergers and acquisitions, product launch, sales force optimization, corporate partnering and research prioritization. He was a Phi Beta Kappa graduate in political science and Morehead Scholar at the University of North Carolina at Chapel Hill and holds an M.B.A. from Harvard Business School.

Robert W. Jevon
Partner, Boston Millennia Partners

Mr. Jevon has been a Partner at Boston Millennia Partners since its founding in 1997.  He was previously a venture partner at Boston Capital Ventures, which he joined in 1996.  Prior to that, he was Managing Director and co-owner of Watch Hill Corporation, a Boston based private investment firm.  Previously, he was Controller of Bolt, Beranek and Newman’s Communications Division.  He also gained significant operational and international experience stationed in Copenhagen as Finance Director of BBN Communications A/S.  His earlier business career included several assignments in General Electric’s Financial Management Program.

Mr. Jevon serves as a Director of Athenix, an agricultural-biotechnology company developing insect and herbicide resistant plants; PHT, a provider of mobile and Web technologies that help pharmaceutical companies simplify clinical trials; and MedAptus, a healthcare information technology company.

Previous investment responsibilities have included Galt Associates, which provides safety and outcomes data management products and services to major pharmaceutical companies (sold to Cerner (Nasdaq: CERN)); eMed, which provides systems to digitally store and transmit radiological images (sold to Cedera Software (NasdaqGM: CDSW)); Proteome, a protein database company (sold to Incyte Genomics (NasdaqGM: INCY)); and, an online recruiting solution (acquired by Yahoo (NasdaqGSL: YHOO)).  Mr Jevon has a BA in economics from Haverford College and holds an MBA from the Amos Tuck School at Dartmouth College.

Robert J. Moccia
CEO, PreCision Dermatology and President, Onset Dermatologics

Mr. Moccia brings over 30 years of dermatology experience to Onset Dermatologics and PreCision Dermatology. Previously, he led Graceway Pharmaceuticals as its President and COO from its establishment in 2007 until its acquisition by Medicis Pharmaceuticals in 2011. Under his leadership, the company marketed the leading drug for the treatment of actinic keratosis and developed a robust pipeline of prescription dermatologic therapies. Formerly, Mr. Moccia was President of Chester Valley Pharmaceuticals, a company he co-founded, and President of Bioglan Pharmaceuticals. Through his career, Mr. Moccia also has held key positions at Medicis Pharmaceuticals and Dermik Laboratories. Mr. Moccia is an expert in creating customer-focused organizations that are widely admired for operational excellence and quality. His areas of expertise include strategy, drug development, licensing, marketing, and sales. Mr. Moccia holds a B.S. degree from Stonehill College.

Adele C. Oliva
Partner, Quaker Partners

Ms. Oliva serves as a partner at Quaker Partners. Prior to her current role, she was a partner at Apax Partners where she co-led the US Healthcare Group, focusing on specialty pharmaceuticals and medical devices. Prior to joining Apax in 1997, Ms. Oliva held positions in marketing and business development with Baxter Healthcare’s Cardiovascular and I.V. Systems divisions. She also worked at CoreStates Financial Corp. as a commercial lending officer and senior financial analyst. Ms. Oliva currently serves on the boards of NovaSom, NY Digital Health Accelerator, and Semprae Laboratories. She holds a B.Sc. in Finance from St. Joseph University and an M.B.A. in Marketing from Cornell University.

William Robb
Partner, NovaQuest Capital Management, LLC.

Mr. Robb is a founder and Partner of NovaQuest Capital Management, a life-sciences private equity fund that focuses on product-based and company investments. The NovaQuest team developed its investment strategy for over 10 years while part of Quintiles Transnational, the world’s leading provider of biopharmaceutical services. During that time, Mr. Robb led gross commitments of more than $1.4 billion in structured investment transactions with multiple small cap and leading global biopharmaceutical companies. Prior to joining Quintiles, he worked in healthcare strategic consulting for The Wilkerson Group and on global development projects in Africa. He graduated with honors from Princeton University and obtained an MBA from The Kellogg Graduate School of Management at Northwestern University, where he majored in corporate finance and healthcare management & strategy.

Immanuel Thangaraj
Managing Director, Essex Woodlands

Mr. Thangaraj has nearly 20 years of experience in healthcare-focused venture capital. Prior to joining Essex Woodlands, he served as an Associate and CFO at ARCH Venture Partners (AVP), a leading venture capital firm targeting early stage technology and healthcare investments. Mr. Thangaraj left AVP to run a start-up telecommunications services company called Integrated Telemanagement, which was later sold to Cam-Net Communications.

Mr. Thangaraj also serves as the Chairman of the Board of Directors for MAP International, is an Advisory Board member for the University of Chicago’s Polsky Center for Entrepreneurship, is an Advisory Board member of the Global Cardiovascular Innovation Center (GCIC) at the Cleveland Clinic and is an Advisory Board Member of Omaha Capital, formerly known as China Medical and Technology Ventures. He currently serves on the Board of Directors of Acura Pharmaceuticals, Clear Vascular, CBR Systems, Medlogics Corporation, Proteus BioMedical, and Sound ID. Mr. Thangaraj holds a B.A. and an M.B.A. from the University of Chicago.